160 related articles for article (PubMed ID: 24560674)
1. Intranasal vaccination with a replication-deficient influenza virus induces heterosubtypic neutralising mucosal IgA antibodies in humans.
Morokutti A; Muster T; Ferko B
Vaccine; 2014 Apr; 32(17):1897-900. PubMed ID: 24560674
[TBL] [Abstract][Full Text] [Related]
2. Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans.
Overton ET; Goepfert PA; Cunningham P; Carter WA; Horvath J; Young D; Strayer DR
Vaccine; 2014 Sep; 32(42):5490-5. PubMed ID: 25128802
[TBL] [Abstract][Full Text] [Related]
3. Induction of Local Secretory IgA and Multifunctional CD4⁺ T-helper Cells Following Intranasal Immunization with a H5N1 Whole Inactivated Influenza Virus Vaccine in BALB/c Mice.
Trondsen M; Aqrawi LA; Zhou F; Pedersen G; Trieu MC; Zhou P; Cox RJ
Scand J Immunol; 2015 May; 81(5):305-17. PubMed ID: 25737202
[TBL] [Abstract][Full Text] [Related]
4. Human immune responses elicited by an intranasal inactivated H5 influenza vaccine.
Ainai A; van Riet E; Ito R; Ikeda K; Senchi K; Suzuki T; Tamura SI; Asanuma H; Odagiri T; Tashiro M; Kurata T; Multihartina P; Setiawaty V; Pangesti KNA; Hasegawa H
Microbiol Immunol; 2020 Apr; 64(4):313-325. PubMed ID: 31957054
[TBL] [Abstract][Full Text] [Related]
5. Characterization of neutralizing antibodies in adults after intranasal vaccination with an inactivated influenza vaccine.
Ainai A; Tamura S; Suzuki T; Ito R; Asanuma H; Tanimoto T; Gomi Y; Manabe S; Ishikawa T; Okuno Y; Odagiri T; Tashiro M; Sata T; Kurata T; Hasegawa H
J Med Virol; 2012 Feb; 84(2):336-44. PubMed ID: 22170556
[TBL] [Abstract][Full Text] [Related]
6. Induction of systemic and mucosal immunity and maintenance of its memory against influenza A virus by nasal vaccination using a new mucosal adjuvant SF-10 derived from pulmonary surfactant in young cynomolgus monkeys.
Mizuno D; Kimoto T; Sakai S; Takahashi E; Kim H; Kido H
Vaccine; 2016 Apr; 34(16):1881-8. PubMed ID: 26954466
[TBL] [Abstract][Full Text] [Related]
7. Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
Tamura S; Ainai A; Suzuki T; Kurata T; Hasegawa H
Jpn J Infect Dis; 2016; 69(3):165-79. PubMed ID: 27212584
[TBL] [Abstract][Full Text] [Related]
8. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
9. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
[TBL] [Abstract][Full Text] [Related]
10. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
[TBL] [Abstract][Full Text] [Related]
11. Induction of cross-neutralizing antibody against H5N1 virus after vaccination with seasonal influenza vaccine in COPD patients.
Kositanont U; Wongsurakiat P; Pooruk P; Maranetra N; Puthavathana P
Viral Immunol; 2010 Jun; 23(3):329-34. PubMed ID: 20565296
[TBL] [Abstract][Full Text] [Related]
12. IgA polymerization contributes to efficient virus neutralization on human upper respiratory mucosa after intranasal inactivated influenza vaccine administration.
Terauchi Y; Sano K; Ainai A; Saito S; Taga Y; Ogawa-Goto K; Tamura SI; Odagiri T; Tashiro M; Fujieda M; Suzuki T; Hasegawa H
Hum Vaccin Immunother; 2018 Jun; 14(6):1351-1361. PubMed ID: 29425074
[TBL] [Abstract][Full Text] [Related]
13. Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine.
Greenbaum E; Engelhard D; Levy R; Schlezinger M; Morag A; Zakay-Rones Z
Vaccine; 2004 Jun; 22(20):2566-77. PubMed ID: 15193382
[TBL] [Abstract][Full Text] [Related]
14. An Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine Is Safe, Immunogenic & Efficacious in the Human Viral Influenza Challenge Model. Serum IgG & Mucosal IgA Are Important Correlates of Protection against Illness Associated with Infection.
Lambkin-Williams R; Gelder C; Broughton R; Mallett CP; Gilbert AS; Mann A; He D; Oxford JS; Burt D
PLoS One; 2016; 11(12):e0163089. PubMed ID: 28005959
[TBL] [Abstract][Full Text] [Related]
15. Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection.
Hong SH; Byun YH; Nguyen CT; Kim SY; Seong BL; Park S; Woo GJ; Yoon Y; Koh JT; Fujihashi K; Rhee JH; Lee SE
Vaccine; 2012 Jan; 30(2):466-74. PubMed ID: 22051136
[TBL] [Abstract][Full Text] [Related]
16. Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults.
Ainai A; Tamura S; Suzuki T; van Riet E; Ito R; Odagiri T; Tashiro M; Kurata T; Hasegawa H
Hum Vaccin Immunother; 2013 Sep; 9(9):1962-70. PubMed ID: 23896606
[TBL] [Abstract][Full Text] [Related]
17. Alkyl polyglycoside, a highly promising adjuvant in intranasal split influenza vaccines.
Wu H; Bao Y; Wang X; Zhou D; Wu W
Hum Vaccin Immunother; 2017 Jun; 13(6):1-9. PubMed ID: 28129034
[TBL] [Abstract][Full Text] [Related]
18. Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus.
Ichinohe T; Ainai A; Ami Y; Nagata N; Iwata N; Kawaguchi A; Suzaki Y; Odagiri T; Tashiro M; Takahashi H; Strayer DR; Carter WA; Chiba J; Tamura S; Sata T; Kurata T; Hasegawa H
J Med Virol; 2010 Oct; 82(10):1754-61. PubMed ID: 20827774
[TBL] [Abstract][Full Text] [Related]
19. Localized mucosal response to intranasal live attenuated influenza vaccine in adults.
Barría MI; Garrido JL; Stein C; Scher E; Ge Y; Engel SM; Kraus TA; Banach D; Moran TM
J Infect Dis; 2013 Jan; 207(1):115-24. PubMed ID: 23087433
[TBL] [Abstract][Full Text] [Related]
20. PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.
Ichinohe T; Ainai A; Tashiro M; Sata T; Hasegawa H
Vaccine; 2009 Oct; 27(45):6276-9. PubMed ID: 19840660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]